Caris Life Sciences, Inc.
CAI
$18.42
-$0.06-0.30%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 292.89M | 216.83M | 181.40M | 120.92M | 129.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 292.89M | 216.83M | 181.40M | 120.92M | 129.92M |
| Cost of Revenue | 70.10M | 69.33M | 67.71M | 63.85M | 57.57M |
| Gross Profit | 222.78M | 147.51M | 113.69M | 57.06M | 72.35M |
| SG&A Expenses | 104.55M | 93.24M | 106.63M | 91.95M | 84.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 204.48M | 184.19M | 199.39M | 178.87M | 166.96M |
| Operating Income | 88.41M | 32.64M | -17.99M | -57.95M | -37.05M |
| Income Before Tax | 81.96M | 24.33M | -71.79M | -102.58M | -36.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 81.96M | 24.33M | -71.79M | -102.58M | -36.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.96M | 24.33M | -71.79M | -102.58M | -36.95M |
| EBIT | 88.41M | 32.64M | -17.99M | -57.95M | -37.05M |
| EBITDA | 92.70M | 37.51M | -11.58M | -50.91M | -27.98M |
| EPS Basic | 0.29 | 0.09 | -7.97 | -3.57 | -1.74 |
| Normalized Basic EPS | 0.19 | 0.05 | -0.52 | -1.80 | -0.65 |
| EPS Diluted | 0.28 | 0.08 | -7.97 | -3.57 | -1.74 |
| Normalized Diluted EPS | 0.18 | 0.05 | -0.52 | -1.80 | -0.65 |
| Average Basic Shares Outstanding | 282.22M | 282.10M | 64.92M | 35.62M | 35.66M |
| Average Diluted Shares Outstanding | 296.09M | 297.21M | 64.92M | 35.62M | 35.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |